BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 1393035)

  • 21. Calcitonin therapy in osteoporosis.
    Muñoz-Torres M; Alonso G; Raya MP
    Treat Endocrinol; 2004; 3(2):117-32. PubMed ID: 15743107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
    Henriksen K; Byrjalsen I; Andersen JR; Bihlet AR; Russo LA; Alexandersen P; Valter I; Qvist P; Lau E; Riis BJ; Christiansen C; Karsdal MA;
    Bone; 2016 Oct; 91():122-9. PubMed ID: 27462009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
    N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
    Ellerington MC; Hillard TC; Whitcroft SI; Marsh MS; Lees B; Banks LM; Whitehead MI; Stevenson JC
    Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R; Sigaud A; Azria M; Herrmann FR
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.
    Kollerup G; Hermann AP; Brixen K; Lindblad BE; Mosekilde L; Sørensen OH
    Calcif Tissue Int; 1994 Jan; 54(1):12-5. PubMed ID: 8118746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of different doses of nasal salmon calcitonin on bone mass.
    Thamsborg G; Storm TL; Sykulski R; Brinch E; Nielsen HK; Sørensen OH
    Calcif Tissue Int; 1991 May; 48(5):302-7. PubMed ID: 2054714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
    N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcitonin for prevention and treatment of osteoporosis.
    Reginster JY
    Am J Med; 1993 Nov; 95(5A):44S-47S. PubMed ID: 8256795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
    Ringe JD; Kipshoven C; Cöster A; Umbach R
    Osteoporos Int; 1999; 9(2):171-8. PubMed ID: 10367046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
    Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
    N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
    Colpan L; Gur A; Cevik R; Nas K; Sarac AJ
    Maturitas; 2005 Jul; 51(3):246-53. PubMed ID: 15978968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.